Receive instant alerts for news on your actions. Claim your 1-week free trial for StreetInsider Premium here.
SOMERSET, NJ – (BUSINESS WIRE) – Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of development science and drug manufacturing platforms, including biotherapeutics; cell and gene therapies; and Consumer Health Products, today announced that its wholly-owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Affiliate”) has priced a private offering (the “Private Offering”). and) in the aggregate principal amount of $ 650 million Notes due 2030 (the “Notes”) at par, representing an increase of $ 200 million from the size of the previously announced offering.
The operating subsidiary intends to use the proceeds of the private offering to fund a portion of the purchase price of the previously announced acquisition of Bettera Holdings, LLC (the “Bettera Acquisition”) and to pay related fees, costs and expenses.
The Notes will be guaranteed by all of the US wholly owned subsidiaries of the Operating Subsidiary which secure its senior secured credit facilities. The Notes will not be guaranteed by PTS Intermediate Holdings, LLC or Catalent, the direct and indirect parent companies of the Operating Subsidiary.
The Private Offer is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Bonds will be offered and sold to persons reasonably considered to be qualified institutional buyers under Rule 144A of the Securities Act and to certain non-US persons outside the United States in accordance with Regulation S of the Securities Act.
The sale of the Bonds is expected to be completed on September 29, 2021, subject to customary closing conditions.
The Notes have not been and will not be registered under the Securities Act or applicable state securities laws and may not be offered or sold in the United States absent registration or approval. applicable exemption from the registration requirements of the Securities Act and applicable state laws.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the Notes or any other security described above and does not constitute an offer, solicitation or sale in any State. jurisdiction in which such offer, solicitation, or sale would be illegal.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the world’s leading provider of development science and drug manufacturing platforms, including biotherapeutics; cell and gene therapies; and consumer health products. With nearly 90 years serving the industry, Catalent has a proven track record of bringing more customer products to market, improving product performance, and ensuring a reliable global supply of clinical and commercial products. Catalent’s workforce exceeds 17,000 people, including more than 2,500 scientists and technicians, in more than 50 facilities on four continents, and in fiscal 2021, it generated $ 4 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information visit www.catalent.com.
Forward-looking statement notice
This press release contains both historical and forward-looking statements, including statements regarding the acquisition of Bettera, the private placement and plans, projections and estimates regarding the use of the proceeds of the private placement. All statements other than statements of historical fact are or may be considered forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can generally be identified because they relate to the matters set out above or by the use of statements that include expressions such as “believe”, “expect”, “anticipate”, “have the intention to ”,“ estimate ”,“ ”plan”, “plan”, “foresee”, “probable”, “may”, “will”, “should” or other words or expressions having similar meanings. Likewise, statements that describe Catalent’s objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If the underlying assumptions prove to be incorrect or if unknown risks or uncertainties materialize, actual results could differ materially from Catalent’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to: the current or future effects of the COVID-19 pandemic on the business of Catalent or its customers or suppliers, participation in a highly competitive market and increased competition may adversely affect Catalent’s business; demand for Catalent’s offerings which depends in part on the research and development of Catalent’s customers and the clinical and commercial success of their products; risks relating to products and other liabilities that could adversely affect Catalent’s results of operations, financial condition, liquidity and cash flow; failure to meet existing and future regulatory requirements; failure to provide quality offerings to customers could adversely affect Catalent’s business and expose it to costly regulatory actions and litigation; problems in providing the highly demanding and complex service or support required; global economic, political and regulatory risks to Catalent’s operations; failure to improve existing service or technology offerings or introduce new ones in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protection; fluctuations in the cost, availability and suitability of components of products manufactured by Catalent, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or reimbursement for health care in the United States or abroad; fluctuations in the exchange rate of the US dollar against other currencies; adverse tax legislative or regulatory initiatives or challenges or adjustments to Catalent’s tax positions; loss of key personnel; the risks generally associated with information systems; the inability to complete any future acquisitions, including the acquisition of Bettera, or any other transaction that may complement or expand Catalent’s business or divest non-core businesses or assets and difficulties in successfully integrating the acquired companies and to realize the expected benefits of these acquisitions; risks associated with on-time and successful completion, and proper anticipation of expected future demand for capital expansion projects at Catalent’s existing facilities; offers and products from customers likely to infringe the intellectual property rights of third parties; environmental, health and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or work difficulties, which could increase costs or cause operational disruptions; additional cash contributions required to fund Catalent’s existing pension plans; substantial leverage resulting from Catalent’s limited ability to raise additional capital to finance its operations and respond to changes in the economy or industry; exposure to interest rate risk in the amount of Catalent’s variable rate debt and preventing Catalent from meeting its debt obligations. For a more detailed discussion of these and other factors, see the information under the heading “Risk Factors” in Catalent’s Annual Report on Form 10-K for the year ended June 30, 2021, filed August 30, 2021. . Statements speak only as of the date of this release or the date on which they are made, and Catalent does not undertake to update any forward-looking statements as a result of new information or future events or developments , except to the extent required by law.
Paul Surdez, 732-537-6325
Source: Catalent, Inc.